Table 3.
Cell cycle analysis of MCF7 cells after treatment for 24 h showing the DNA content (mean ± SEM) at different cycle phases
| Drug | Cell cycle phases | |||
|---|---|---|---|---|
| SubG0/G1 | G0/1 | S | G2/M | |
| Control | 10.90 ± 0.60 | 42.5 ± 0.8 | 16.3 ± 1.10 | 30.1 ± 1.10 |
| Dox | 12.86 ± 1.25 | 31.1 ± 0.60 | 17.65 ± 0.35 | 40.2 ± 0.70 |
| Cyclo | 10.05 ± 0.85 | 31.7 ± 1.70 | 25 ± 1.20 | 35.8 ± 0.20 |
| Pitavastatin | 18.00 ± 0.60 | 42.9 ± 1.80 | 39.7 ± 1.60 | 0.9 ± 0.20 |
| Simvastatin | 17.95 ± 2.25 | 49.05 ± 1.55 | 31.25 ± 1.85 | 1.4 ± 0.10 |
| Dox/ cyclo | 21.75 ± 0.55 | 51 ± 0.90 | 2.85 ± 0.65 | 26.5 ± 0.70 |
| Dox/ cyclo + Pitavastatin | 23.15 ± 0.45 | 62.15 ± 2.05 | 4.6 ± 0.30 | 12.9 ± 0.10 |
| Dox/ cyclo + simvastatin | 22.50 ± 1.60 | 65.2 ± 2.10 | 6.5 ± 1.20 | 10.2 ± 10 |
G0/G1: growth phase 0/1, S: synthesis phase, G2/M: growth phase 2, and mitosis phase. Control sets as untreated cells; Dox: doxorubicin (12.5 µg/ml), Cyclo: cyclophosphamide (100 µM), Pitavastatin (50 µM), simvastatin (25 µM).